These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32455942)

  • 21. Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.
    Yamamoto M; Gohda J; Kobayashi A; Tomita K; Hirayama Y; Koshikawa N; Seiki M; Semba K; Akiyama T; Kawaguchi Y; Inoue JI
    mBio; 2022 Aug; 13(4):e0051922. PubMed ID: 35708281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2.
    Li X; Zai J; Zhao Q; Nie Q; Li Y; Foley BT; Chaillon A
    J Med Virol; 2020 Jun; 92(6):602-611. PubMed ID: 32104911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A substrate for a cell free in vitro assay system to screen drugs targeting trypsin like protease-based cleavage of SARS-CoV-2 spike glycoprotein and viral entry.
    Begum F; Srivastava AK; Tripathi PP; Ray U
    J Med Virol; 2023 May; 95(5):e28796. PubMed ID: 37218551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.
    Kishk SM; Kishk RM; Yassen ASA; Nafie MS; Nemr NA; ElMasry G; Al-Rejaie S; Simons C
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33137894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Properties of Coronavirus and SARS-CoV-2.
    Malik YA
    Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteolytic activation of SARS-CoV-2 spike protein.
    Takeda M
    Microbiol Immunol; 2022 Jan; 66(1):15-23. PubMed ID: 34561887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of angiotensin-converting enzyme 2 and proteases in COVID-19 patients: A potential role of cellular FURIN in the pathogenesis of SARS-CoV-2.
    Drak Alsibai K
    Med Hypotheses; 2020 Oct; 143():109893. PubMed ID: 32512290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization.
    Bongini P; Trezza A; Bianchini M; Spiga O; Niccolai N
    Biochem Biophys Res Commun; 2020 Jul; 528(1):35-38. PubMed ID: 32451080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.
    Cheng YW; Chao TL; Li CL; Chiu MF; Kao HC; Wang SH; Pang YH; Lin CH; Tsai YM; Lee WH; Tao MH; Ho TC; Wu PY; Jang LT; Chen PJ; Chang SY; Yeh SH
    Cell Rep; 2020 Oct; 33(2):108254. PubMed ID: 33007239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity.
    Drew ED; Janes RW
    BMC Mol Cell Biol; 2020 Jul; 21(1):49. PubMed ID: 32611313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
    Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V.
    Bollavaram K; Leeman TH; Lee MW; Kulkarni A; Upshaw SG; Yang J; Song H; Platt MO
    Protein Sci; 2021 Jun; 30(6):1131-1143. PubMed ID: 33786919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
    Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
    Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin.
    Tang T; Jaimes JA; Bidon MK; Straus MR; Daniel S; Whittaker GR
    ACS Infect Dis; 2021 Feb; 7(2):264-272. PubMed ID: 33432808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure of Furin Protease Binding to SARS-CoV-2 Spike Glycoprotein and Implications for Potential Targets and Virulence.
    Vankadari N
    J Phys Chem Lett; 2020 Aug; 11(16):6655-6663. PubMed ID: 32787225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
    Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
    Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
    Huang Y; Yang C; Xu XF; Xu W; Liu SW
    Acta Pharmacol Sin; 2020 Sep; 41(9):1141-1149. PubMed ID: 32747721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation of Proteolytic Cleavage Sites towards the N-Terminal End of the S2 Subunit of the Novel SARS-CoV-2 Omicron Sublineage BA.2.12.1.
    Schilling NA; Kalbacher H; Burster T
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.